Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2698678 | 0.92 | LMNA (0.60) | LMNAMAPTALDH1A1HCAR3PTGER4 | |
| SCHEMBL5523378 | 0.81 | LMNA (0.66) | LMNAMAPTALDH1A1HCAR3PTGER4 | |
| SCHEMBL5519443 | 0.81 | LMNA (0.66) | LMNAMAPTALDH1A1HCAR3PTGER4 | |
| SCHEMBL5519436 | 0.80 | LMNA (0.64) | LMNAMAPTALDH1A1HCAR3PTGER4 | |
| SCHEMBL2700000 | 0.78 | LMNA (0.64) | LMNAMAPTALDH1A1HCAR3PTGER4 | |
| SCHEMBL2696972 | 0.77 | ALDH1A1 (0.46) | LMNAMAPTALDH1A1HCAR3RAB9A | |
| SCHEMBL15774533 | 0.74 | LMNA (0.66) | LMNAMAPTALDH1A1HCAR3PTGER4 | |
| SCHEMBL2698755 | 0.74 | LMNA (0.66) | LMNAMAPTALDH1A1HCAR3PTGER4 | |
| SCHEMBL2554303 | 0.74 | HCAR3 (0.67) | LMNAMAPTALDH1A1HCAR3PTGER4 | |
| SCHEMBL2698365 | 0.73 | LMNA (0.64) | LMNAMAPTALDH1A1HCAR3PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | PTGES, PTGS1, PTGIS | LMNA 3574/4885MAPT 910/4885ALDH1A1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.